ArticleFrontiers in immunology2026
Identification of key genes related to arginine metabolism in immunoglobulin A nephropathy through the combination of scRNA-seq and bulk RNA-seq data.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immunoglobulin A nephropathy (IgAN) is a major cause of chronic kidney disease and kidney failure. Currently, arginine metabolism (AM)-related genes (AMRGs) have been reported to play direct or indirect roles in various kidney-related diseases. This study aimed to identify AM-associated key genes in IgAN, potentially paving the way for targeted therapies. Methods: The data pertaining to IgAN and AMRGs were procured from public databases and literature, respectively. Candidate genes were obtained by integrating differentially expressed genes (DEGs) with AMRGs, and the genes were experimentally verified using qPCR. The identification of key genes was facilitated by machine learning algorithms and gene expression analyses. Of particular significance was the use of the nomogram to evaluate the diagnostic efficacy of these key genes. Functional enrichment, immune infiltration, drug prediction, and molecular docking analyses were performed. Single-cell analysis was employed to ascertain cell types, with the identification of key cells facilitated by key genes. Results: ARG1 and ARG2 were identified as key genes, and the expression of these 2 genes was found to be downregulated in IgAN samples. The nomogram developed utilizing these key genes demonstrated a satisfactory capacity for differentiating among various sample types. The key genes were found to be enriched in several signaling pathways, including PIP3 signaling in B lymphocytes and BCR signaling pathway. Furthermore, most of the differential immune cells showed significant negative correlations with key genes. Effector memory CD8+ T cells exhibited extremely significant negative correlations with both ARG1 and ARG2 (correlation coefficient (r) < -0.70, P < 0.001). Riluzole exhibited strong binding affinity for key genes and formed stable complexes. Finally, monocytes were considered key cells and played a critical role in IgAN. Conclusion: This study suggests that ARG1 and ARG2 may be key genes and potential mechanistic indicators of IgAN associated with AM, but it needs to be further verified in non-invasive samples and larger independent cohorts. Additionally, monocytes were recognized as key cells in the progression of IgAN, providing valuable insights to support the development of targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.